Charm Therapeutics
Charm Therapeutics develops medicines by predicting protein-ligand interactions to treat diseases like Acute Myeloid Leukemia (AML). The company is currently advancing a menin inhibitor designed to bind within the KMT2A interface to address resistance issues found in earlier treatments. Its platform utilizes expertise in AI and drug discovery to create structurally optimized inhibitors for clinical use.
Visit websiteLondon, UK
AI
Biotechnology
Healthcare
Drug Discovery
Funding summary
- Total raised
- €116.0M
- Funding rounds
- 2
Investors in Charm Therapeutics
Investors on record for Charm Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Charm Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors